177785-41-0

Basic information

• Product Name: 4-Amino-N-cyclopropylbenzene-1-sulfonamide
• Synonyms: N-Cyclopropyl 4-Aminophenylsulfonamide;4-Amino-N-cyclopropylbenzene-1-sulfonamide
• CAS NO: 177785-41-0
• Molecular Formula: C9H12N2O2S
• Molecular Weight: 212.27
• Product Categories: Acids and Derivatives;Amines and Anilines
• Mol File: 177785-41-0.mol

Chemical Properties

• Boiling Point: 401°C at 760 mmHg
• Flash Point: 196.3°C
• Appearance: /
• Density: 1.39g/cm³
• Vapor Pressure: 1.22E-06mmHg at 25°C
• Refractive Index: 1.637
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-Amino-N-cyclopropylbenzene-1-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-N-cyclopropylbenzene-1-sulfonamide(177785-41-0)
• EPA Substance Registry System: 4-Amino-N-cyclopropylbenzene-1-sulfonamide(177785-41-0)

Safety Data

• Hazardous Substances Data: 177785-41-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Amino-N-cyclopropylbenzene-1-sulfonamide is used as a potential antibacterial or antifungal agent for its possible inhibitory effect on enzymes involved in folate synthesis. The presence of the sulfonamide group is indicative of its potential utility in treating a range of bacterial and fungal infections.
Further studies are essential to delineate the compound's biological activity and to establish its therapeutic efficacy and safety profile, which would be crucial for its development as a novel treatment option in the medical field.

InChI:InChI=1/C9H12N2O2S/c10-7-1-5-9(6-2-7)14(12,13)11-8-3-4-8/h1-2,5-6,8,11H,3-4,10H2

Upstream product

• 98-74-8 4-Nitrobenzenesulfonyl chloride 
• 765-30-0 Cyclopropylamine 
• 549476-61-1 N-cyclopropyl-4-nitrobenzenesulfonamide 

Relevant articles and documents

Synthesis and biological evaluation of norcantharidin derivatives as protein phosphatase-1 inhibitors

Cantharidin and norcantharidin display anticancer activity against a broad range of tumor cell lines. In this study, we have synthesized a series of norcantharidin derivatives and evaluated their cytotoxic effects on four human tumor cell lines together with the genetically normal human diploid fibroblast line WI-38. One of our compounds (1S,4R)-3-((4-(4-(4-fluorophenyl)piperazin-1-ylsulfonyl) phenyl)carbamoyl)-7-oxa-bicyclo[2.2.1]heptane-2-carboxylic acid (12) exhibited potent cytotoxic effects on the tumor cell lines A-549, HepG2, HeLa, and HCT-8, whereas it was less toxic to WI-38 cells than its parent compound, norcantharidin. In addition, this compound inhibited protein phosphatase-1 activity and microtubule formation in HeLa cells, and it also interacts with calf thymus DNA.

Combining organometallic reagents, the sulfur dioxide surrogate DABSO, and amines: A One-pot preparation of sulfonamides, amenable to array synthesis

We describe a method for the synthesis of sulfonamides through the combination of an organometallic reagent, a sulfur dioxide equivalent, and an aqueous solution of an amine under oxidative conditions (bleach). This simple reaction protocol avoids the need to employ sulfonyl chloride substrates, thus removing the limitation imposed by the commercial availability of these reagents. The resultant method allows access to new chemical space, and is also tolerant of the polar functional groups needed to impart favorable physiochemical properties required for medicinal chemistry and agrochemistry. The developed chemistry is employed in the synthesis of a targeted 70 compound array, prepared using automated methods. The array achieved a 93% success rate for compounds prepared. Calculated molecular weights, lipophilicities, and polar surface areas are presented, demonstrating the utility of the method for delivering sulfonamides with drug-like properties.

Synthesis and SAR of novel, 4-(phenylsulfamoyl)phenylacetamide mGlu 4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS)

Herein we disclose the synthesis and SAR of a series of 4-(phenylsulfamoyl)phenylacetamide compounds as mGlu4 positive allosteric modulators (PAMs) that were identified via a functional HTS. An iterative parallel approach to these compounds culminated in the discovery of VU0364439 (11) which represents the most potent (19.8 nM) mGlu4 PAM reported to date.

NOVEL ADENOSINE A3 RECEPTOR AGONISTS

The invention realizes that a series of sulfonamido derivatives with a conserved uronamide group at the 5' position provide superior A3 receptor affinity as well as selectivity. These new adenosine agonists are sulfonamido deritatives N-substituted with aliphatic groups (cyclic or linear) or aromatic radicals.

IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES

A compound of formula (I) wherein Ring A is imidazol[1,2a]pyrid-3-yl or pyrazolo[2,3a]pyrid-3-yl; Ris as defined within; m is 0-5; wherein the values of Rmay be the same or different; Ris as defined within; n is 0 to 2, wherein the values of Rmay be the same or different; Ring B is phenyl or phenyl fused to a C5-7cycloalkyl ring; Ris as defined within; p is 0-4; wherein the values of Rmay be the same or different; Ris as defined within; q is 0-2; wherein the values of Rmay be the same or different; and wherein p+q=5; or a pharmaceutically acceptable salt or an in vivo hydrolyzable ester thereof is described. The use of compounds of formula (I) in the inhibition of cell cycle kinases CDK2, CDK4, and CDK6 are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.